相似文献
1
The role of B cells in the immunopathogenesis of multiple sclerosis.
Immunology. 2020 Aug;160(4):325-335. doi: 10.1111/imm.13198. Epub 2020 May 10.
2
Reassessing B cell contributions in multiple sclerosis.
Nat Immunol. 2018 Jul;19(7):696-707. doi: 10.1038/s41590-018-0135-x. Epub 2018 Jun 20.
3
The Multiple Roles of B Cells in Multiple Sclerosis and Their Implications in Multiple Sclerosis Therapies.
Cold Spring Harb Perspect Med. 2019 Apr 1;9(4):a029108. doi: 10.1101/cshperspect.a029108.
4
Further understanding of the immunopathology of multiple sclerosis: impact on future treatments.
Expert Rev Clin Immunol. 2016 Oct;12(10):1069-89. doi: 10.1080/1744666X.2016.1191351. Epub 2016 Jun 23.
5
Memory B Cells in Multiple Sclerosis: Emerging Players in Disease Pathogenesis.
Front Immunol. 2021 Jun 8;12:676686. doi: 10.3389/fimmu.2021.676686. eCollection 2021.
6
The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies.
Curr Opin Neurol. 2008 Apr;21 Suppl 1:S9-S18. doi: 10.1097/01.wco.0000313359.61176.15.
7
B and T Cells Driving Multiple Sclerosis: Identity, Mechanisms and Potential Triggers.
Front Immunol. 2020 May 8;11:760. doi: 10.3389/fimmu.2020.00760. eCollection 2020.
8
B cells and multiple sclerosis.
Lancet Neurol. 2008 Sep;7(9):852-8. doi: 10.1016/S1474-4422(08)70192-3.
9
Multiple Sclerosis: New Aspects of Immunopathogenesis.
Acta Clin Croat. 2018 Jun;57(2):352-361. doi: 10.20471/acc.2018.57.02.17.
10
Cooperation of B cells and T cells in the pathogenesis of multiple sclerosis.
Results Probl Cell Differ. 2010;51:115-26. doi: 10.1007/400_2009_21.
引用本文的文献
1
NETosis in hypersensitivity disorders.
Mol Biol Rep. 2025 Jun 9;52(1):574. doi: 10.1007/s11033-025-10629-6.
2
Overtime Challenges of Diagnosis and Treatment in Two Pediatric Patients with Extensive Cerebral Tumefactive Lesions Indicative of Baló's Type Multiple Sclerosis.
Children (Basel). 2025 May 14;12(5):630. doi: 10.3390/children12050630.
3
Lycopene Supplemented Mediterranean Diet Ameliorates Experimental Autoimmune Encephalomyelitis (EAE) in Mice and Changes Intestinal Microbiome.
J Neuroimmune Pharmacol. 2025 May 5;20(1):50. doi: 10.1007/s11481-025-10212-7.
4
[Multiple sclerosis and the Epstein-Barr Virus: Current perspectives on their pathogenic mechanisms].
Rev Med Inst Mex Seguro Soc. 2025 Mar 3;63(2):e6391. doi: 10.5281/zenodo.14617124.
5
Alterations in neutrophil mRNA profiles in multiple sclerosis and identification of candidate genes for further investigation.
Front Neurol. 2025 Feb 17;16:1548196. doi: 10.3389/fneur.2025.1548196. eCollection 2025.
6
Pathway analysis of peripheral blood CD8+ T cell transcriptome shows differential regulation of sphingolipid signaling in multiple sclerosis and glioblastoma.
PLoS One. 2024 Jun 11;19(6):e0305042. doi: 10.1371/journal.pone.0305042. eCollection 2024.
7
Revolutionizing Neurological Disorder Treatment: Integrating Innovations in Pharmaceutical Interventions and Advanced Therapeutic Technologies.
Curr Pharm Des. 2024;30(19):1459-1471. doi: 10.2174/0113816128284824240328071911.
8
EBNA1 Inhibitors Block Proliferation of Spontaneous Lymphoblastoid Cell Lines From Patients With Multiple Sclerosis and Healthy Controls.
Neurol Neuroimmunol Neuroinflamm. 2023 Aug 10;10(5). doi: 10.1212/NXI.0000000000200149. Print 2023 Sep.
9
Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis.
Neurol Sci. 2023 Sep;44(9):3045-3057. doi: 10.1007/s10072-023-06794-w. Epub 2023 Apr 17.
10
Recent Progress in Multiple Sclerosis Treatment Using Immune Cells as Targets.
Pharmaceutics. 2023 Feb 22;15(3):728. doi: 10.3390/pharmaceutics15030728.
本文引用的文献
1
IL-21 and IL-21-producing T cells are involved in multiple sclerosis severity and progression.
Immunol Lett. 2019 Dec;216:12-20. doi: 10.1016/j.imlet.2019.09.003. Epub 2019 Sep 20.
2
The role of immune regulatory molecules in multiple sclerosis.
J Neuroimmunol. 2019 Dec 15;337:577061. doi: 10.1016/j.jneuroim.2019.577061. Epub 2019 Sep 5.
3
Myeloid-derived suppressor cells control B cell accumulation in the central nervous system during autoimmunity.
Nat Immunol. 2018 Dec;19(12):1341-1351. doi: 10.1038/s41590-018-0237-5. Epub 2018 Oct 29.
4
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
Neurology. 2018 May 15;90(20):e1805-e1814. doi: 10.1212/WNL.0000000000005516. Epub 2018 Apr 25.
5
Multiple Sclerosis Pathology.
Cold Spring Harb Perspect Med. 2018 Mar 1;8(3):a028936. doi: 10.1101/cshperspect.a028936.
6
Clinical Course of Multiple Sclerosis.
Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):a028928. doi: 10.1101/cshperspect.a028928.
7
Effector T Cells in Multiple Sclerosis.
Cold Spring Harb Perspect Med. 2018 Apr 2;8(4):a029025. doi: 10.1101/cshperspect.a029025.
8
Regulatory T Cells: From Discovery to Autoimmunity.
Cold Spring Harb Perspect Med. 2018 Dec 3;8(12):a029041. doi: 10.1101/cshperspect.a029041.
9
Teriflunomide treatment reduces B cells in patients with MS.
Neurol Neuroimmunol Neuroinflamm. 2017 Oct 23;4(6):e403. doi: 10.1212/NXI.0000000000000403. eCollection 2017 Nov.
10
Fingolimod induces BAFF and expands circulating transitional B cells without activating memory B cells and plasma cells in multiple sclerosis.
Clin Immunol. 2018 Feb;187:95-101. doi: 10.1016/j.clim.2017.10.009. Epub 2017 Oct 25.
Zotero 插件